NasdaqGM:AXSM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	251	-296	348	117
31 Dec 23	271	-239	323	98
30 Sep 23	223	-202	297	82
30 Jun 23	182	-184	255	68
31 Mar 23	145	-159	208	63
31 Dec 22	50	-187	159	58
30 Sep 22	26	-160	117	57
30 Jun 22	9	-150	96	55
31 Mar 22	0	-141	81	54
31 Dec 21	0	-130	67	58
30 Sep 21	0	-126	58	62
30 Jun 21	0	-114	44	63
31 Mar 21	0	-100	35	59
31 Dec 20	0	-103	29	70
30 Sep 20	0	-99	24	62
30 Jun 20	0	-95	21	63
31 Mar 20	0	-90	16	63
31 Dec 19	0	-68	14	54
30 Sep 19	0	-53	11	41
30 Jun 19	0	-42	10	32
31 Mar 19	0	-37	10	26
31 Dec 18	0	-31	9	23
30 Sep 18	0	-29	9	21
30 Jun 18	0	-27	9	19
31 Mar 18	0	-26	8	19
31 Dec 17	0	-29	7	20
30 Sep 17	0	-29	7	21
30 Jun 17	0	-30	7	22
31 Mar 17	0	-29	7	22
31 Dec 16	0	-27	6	21
30 Sep 16	0	-23	5	18
30 Jun 16	0	-21	4	14
31 Mar 16	0	-16	3	10
31 Dec 15	0	-12	2	7
30 Sep 15	0	-10	2	6
30 Jun 15	0	-6	2	6
31 Mar 15	0	-6	2	5
31 Dec 14	0	-6	1	4

양질의 수익: AXSM 은(는) 현재 수익성이 없습니다.

이익 마진 증가: AXSM 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: AXSM 은(는) 수익성이 없으며 지난 5년 동안 연간 30.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 AXSM 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: AXSM 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 19.9% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: AXSM 현재 수익성이 없기 때문에 마이너스 자본 수익률( -205.77% )을 갖습니다.

Axsome Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Recent updates

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Consensus EPS estimates fall by 25%

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

COO & Secretary exercised options and sold US$1.9m worth of stock

Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Independent Lead Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Full year 2023 earnings: EPS misses analyst expectations

Axsome Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics Appoints Sue Mahony to Its Board of Directors

Axsome Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Independent Director notifies of intention to sell stock

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Consensus EPS estimates fall by 12%, revenue upgraded

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Axsome Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Axsome Therapeutics Initiates Focus Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (Adhd) in Adults

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Axsome Therapeutics, Inc. to Present New Sunosi Data at Sleep 2023

Consensus revenue estimates increase by 45%

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Consensus EPS estimates fall by 27%

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Axsome Therapeutics, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Forecast to breakeven in 2025

Axsome Therapeutics Presents New Data from the Evolve Open-Label Trial Demonstrating Effects of Auvelity® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder At the American College of Neuropsychopharmacology (Acnp) 2022 Annual Meeting

Price target increased to US$109

Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

Insufficient new directors

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Axsome Therapeutics, Inc. Announces Availability of Auvelity, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

No longer forecast to breakeven

Axsome Therapeutics: Clear Path Ahead For AXS07

Axsome Therapeutics, Inc. Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the Sharp Trial in Cognitively Impaired Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea

Axsome Therapeutics, Inc. Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Axsome Therapeutics, Inc. Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

Forecast to breakeven in 2024

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

Axsome Therapeutics Initiates EMERGE Phase 3 Open-Label Trial of AXS-07 for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Price target increased to US$92.93

Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Axsome gains 19% as FDA approves depression therapy

No longer forecast to breakeven

Axsome Therapeutics Q2 2022 Earnings Preview

Axsome Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Axsome: Breaking Bearish Trend